Contract Services Clinical Research

Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers

87% of respondents deemed mRNA a key modality for the future More than 60% of vaccine makers surveyed plan revamp or new facilities for mRNA m...

 May 31, 2023 | News

Immorna Initiates Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine

"The initiation of our FIH study with JCXH-105 is an important milestone for Immorna and for the development of a potential innovative vaccine for Shingles...

 May 31, 2023 | News

Menarini Group's ORSERDU® (Elacestrant) Study Advances in Metastatic Breast Cancer

ORSERDU (elacestrant) was approved by the FDA in January 2023 for advanced or metastatic estrogen receptor (ER)-positive, human epidermal growth factor (...

 May 30, 2023 | News

Keio and Osaka Universities Present Non-Clinical Data on Stable/Functional-Induced Regulatory T Cells in Autoimmune Models

Their presentation demonstrated that in a murine pemphigus model, S/F-iTregs significantly decreased clinical scores, circulating anti-Dsg3 IgG titers, and...

 May 30, 2023 | News

Amplo Biotech Secures Fast Track Funding for Promising Gene Therapy Targeting Collagen Q Deficiency

Under an exclusive licensing agreement, Amplo Biotechnology has gained access to AAV-ColQ data developed by Professor Kinji Ohno's laboratory at&...

 May 30, 2023 | News

Bristol Myers Squibb receives positive CHMP opinion for Opdivo as neoadjuvant treatment for high-risk non-small cell lung cancer

If approved, Opdivo with chemotherapy would be the first and only neoadjuvant immunotherapy-based option authorized to treat patients with non-sm...

 May 29, 2023 | Regulatory

Thermo Fisher Scientific and BRIN to Strengthen Research Infrastructure and Capabilities in Indonesia

Thermo Fisher, the world leader in serving science, has signed a Memorandum of Understanding ("MOU") with the National Research and Innovation Agency of&nb...

 May 26, 2023 | News

Avance Clinical Joins Global Heath Summit Campaign for Faster Access to Life-Changing and Life-Saving Therapies

Avance Clinical CEO, Yvonne Lungershausen, Chief Scientific Officer Gabriel Kremmidiotis, and Head of Scientific and Regulatory Affairs Jorgen Mould are in...

 May 25, 2023 | News

Oncodesign and Veritas In Silico Collaborate on mRNA-Targeted Drug Development

The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional pro...

 May 25, 2023 | News

Antengene's ATG-022 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers

Orphan Drugs, also known as Rare Disease Drugs, refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases o...

 May 24, 2023 | News

Thermo Fisher Scientific Expands Steriles Manufacturing and Research Capabilities in Asia-Pacific Region

Thermo Fisher Scientific, the world leader in serving science, has opened a new sterile drug facility in Singapore that will better enable customers to del...

 May 19, 2023 | News

Discovery Life Sciences Joins Akoya Biosciences' Global Network to Boost Immuno-Oncology Research

With this qualification, Discovery gains access to Akoya's PhenoImager® HT workflows, which can provide insights into the tumor microenvironment (...

 May 19, 2023 | News

Antengene Clears U.S. IND for Phase I Trial of ATG-031 Antibody

-  ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncolog...

 May 18, 2023 | News

BPAC and Novari Health Announce eReferral Integration

This bi-directional integration enables clinicians using the BPAC eReferral system to transmit referrals from within their practice management solution (PM...

 May 16, 2023 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close